You are here: Industry Insights > Biologics

News List

Popular APIs of the Year at Pharmasources.com PharmaSources
December 10, 2024
What are the APIs that caught the highest attention in the year at PharmaSources.com？
Global Drug Innovation Trend and Its Market Landscape Shruti Talashi
September 25, 2024
The creation of novel medications, treatments, and medical equipment that improve patient care and treatment results or outcomes is referred to as pharmaceutical innovation.
Research Progress on the Application of Biologics in Pediatric Asthma Xiaomichong
July 19, 2024
Asthma is a heterogeneous and complex chronic disease. Children with severe asthma often experience acute exacerbations, ultimately leading to impaired lung function and poor quality of life.
Common Treatments for Rheumatoid Arthritis David Orchard-Webb
July 01, 2024
Rheumatoid arthritis (RA) is a chronic inflammatory disorder that primarily affects joints but can also impact other systems in the body, including the skin, eyes, lungs, heart, and blood vessels.
Introduction of FDA Regulatory Education for Industry (REdI) Annual Conference 2021 Lin Zhang
August 16, 2021
There are many educational events in FDA throughout the year that focus on the pharmaceutical and regulatory industries.
Pharmaceutical News of the Week | CPhI.CN - Volumn-based Procurement PharmaSources/Caicai
August 06, 2020
According to the key content spread on the internet on July 28 regarding the national centralized procurement meeting held on July 24.
Eleva and 3PBIOVIAN Sign Strategic GMP Manufacturing and Technology Alliance to Boost Capacity for Eleva’s Platform and Pipeline PharmaSources
February 05, 2025
Eleva and 3PBIOVIAN sign a strategic GMP manufacturing and technology alliance to boost capacity for Eleva's platform and pipeline.
Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform PRNewswire
January 31, 2025
Telix completes the acquisition from ImaginAb, getting a drug pipeline and a biologics technology platform.
I-Mab Expands U.S. Footprint with New R&D Site in San Diego prnasia
October 25, 2021
I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that...
Eleva Reaches Industrial Production Scale and Prepares for Clinical Development of Factor H prnasia
September 23, 2021
Eleva, a manufacturer of superior biologics, is scaling up its production capacity to 2500 l in state-of-the-art single-use reactors. This will produce enough factor H to cover all three clinical phases.

Previous page 1 2 3 4 5 6 7 8 9 Next page